Frazier Life Sciences Viii, L.p. - Net Worth and Insider Trading
Frazier Life Sciences Viii, L.p. Net Worth
The estimated net worth of Frazier Life Sciences Viii, L.p. is at least $187 Million dollars as of 2024-09-20. Frazier Life Sciences Viii, L.p. is the 10% Owner of Alpine Immune Sciences Inc and owns about 1,484,115 shares of Alpine Immune Sciences Inc (ALPN) stock worth over $96 Million. Frazier Life Sciences Viii, L.p. is the 10% Owner of Arcutis Biotherapeutics Inc and owns about 8,827,261 shares of Arcutis Biotherapeutics Inc (ARQT) stock worth over $87 Million. Frazier Life Sciences Viii, L.p. is also the 10% Owner of Entasis Therapeutics Holdings Inc and owns about 1,299,953 shares of Entasis Therapeutics Holdings Inc (ETTX) stock worth over $3 Million. Besides these, Frazier Life Sciences Viii, L.p. also holds Aptinyx Inc (APTX) . Details can be seen in Frazier Life Sciences Viii, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Frazier Life Sciences Viii, L.p. has not made any transactions after 2023-10-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Frazier Life Sciences Viii, L.p.
Frazier Life Sciences Viii, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Frazier Life Sciences Viii, L.p. owns 5 companies in total, including Arcutis Biotherapeutics Inc (ARQT) , Entasis Therapeutics Holdings Inc (ETTX) , and Alpine Immune Sciences Inc (ALPN) among others .
Insider Ownership Summary of Frazier Life Sciences Viii, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ARQT | Arcutis Biotherapeutics Inc | 2023-10-24 | 10 percent owner |
| ETTX | Entasis Therapeutics Holdings Inc | 2020-01-09 | 10 percent owner |
| ALPN | Alpine Immune Sciences Inc | 2022-02-11 | 10 percent owner |
 | | 2018-06-25 | 10 percent owner |
| | 2017-02-14 | 10 percent owner |
Frazier Life Sciences Viii, L.p. Latest Holdings Summary
Frazier Life Sciences Viii, L.p. currently owns a total of 4 stocks. Among these stocks, Frazier Life Sciences Viii, L.p. owns 1,484,115 shares of Alpine Immune Sciences Inc (ALPN) as of February 11, 2022, with a value of $96 Million and a weighting of 51.57%. Frazier Life Sciences Viii, L.p. owns 8,827,261 shares of Arcutis Biotherapeutics Inc (ARQT) as of October 24, 2023, with a value of $87 Million and a weighting of 46.74%. Frazier Life Sciences Viii, L.p. also owns 1,299,953 shares of Entasis Therapeutics Holdings Inc (ETTX) as of January 9, 2020, with a value of $3 Million and a weighting of 1.52%. The other 1 stocks Aptinyx Inc (APTX) have a combined weighting of 0.16% among all his current holdings.
Latest Holdings of Frazier Life Sciences Viii, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ALPN | Alpine Immune Sciences Inc | 2022-02-11 | 1,484,115 | 64.97 | 96,422,952 |
| ARQT | Arcutis Biotherapeutics Inc | 2023-10-24 | 8,827,261 | 9.90 | 87,389,001 |
| ETTX | Entasis Therapeutics Holdings Inc | 2020-01-09 | 1,299,953 | 2.19 | 2,846,897 |
| APTX | Aptinyx Inc | 2018-06-25 | 3,190,079 | 0.10 | 306,248 |
Holding Weightings of Frazier Life Sciences Viii, L.p.
Frazier Life Sciences Viii, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Frazier Life Sciences Viii, L.p. has made a total of 1 transactions in Alpine Immune Sciences Inc (ALPN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Alpine Immune Sciences Inc is the acquisition of 112,665 shares on February 11, 2022, which cost Frazier Life Sciences Viii, L.p. around $799,922.
According to the SEC Form 4 filings, Frazier Life Sciences Viii, L.p. has made a total of 3 transactions in Arcutis Biotherapeutics Inc (ARQT) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Arcutis Biotherapeutics Inc is the acquisition of 80,000 shares on October 24, 2023, which cost Frazier Life Sciences Viii, L.p. around $200,000.
According to the SEC Form 4 filings, Frazier Life Sciences Viii, L.p. has made a total of 1 transactions in Entasis Therapeutics Holdings Inc (ETTX) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Entasis Therapeutics Holdings Inc is the sale of 50,000 shares on January 9, 2020, which brought Frazier Life Sciences Viii, L.p. around $250,000.
More details on Frazier Life Sciences Viii, L.p.'s insider transactions can be found in the Insider Trading History of Frazier Life Sciences Viii, L.p. table.Insider Trading History of Frazier Life Sciences Viii, L.p.
- 1
Frazier Life Sciences Viii, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Frazier Life Sciences Viii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Frazier Life Sciences Viii, L.p. is 10.7%. GuruFocus also compares Frazier Life Sciences Viii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Frazier Life Sciences Viii, L.p. within 3 months outperforms 5 times out of 7 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Frazier Life Sciences Viii, L.p.'s insider trading performs compared to the benchmark.
Performance of Frazier Life Sciences Viii, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -5.98 | | | | | |
| Relative Return to S&P 500(%) | -4.83 | | | | | |
Frazier Life Sciences Viii, L.p. Ownership Network
Frazier Life Sciences Viii, L.p. Owned Company Details
What does Arcutis Biotherapeutics Inc do?
Who are the key executives at Arcutis Biotherapeutics Inc?
Frazier Life Sciences Viii, L.p. is the 10 percent owner of Arcutis Biotherapeutics Inc. Other key executives at Arcutis Biotherapeutics Inc include See Remarks Patrick Burnett , director & President and CEO Todd Franklin Watanabe , and SVP and General Counsel Masaru Matsuda .
Arcutis Biotherapeutics Inc (ARQT) Insider Trades Summary
Over the past 18 months, Frazier Life Sciences Viii, L.p. made 1 insider transaction in Arcutis Biotherapeutics Inc (ARQT) with a net purchase of 80,000. Other recent insider transactions involving Arcutis Biotherapeutics Inc (ARQT) include a net sale of 103,828 shares made by Patrick Burnett , a net sale of 57,000 shares made by Howard G. Welgus , and a net sale of 19,451 shares made by Masaru Matsuda .
In summary, during the past 3 months, insiders sold 64,641 shares of Arcutis Biotherapeutics Inc (ARQT) in total and bought 0 shares, with a net sale of 64,641 shares. During the past 18 months, 241,706 shares of Arcutis Biotherapeutics Inc (ARQT) were sold and 102,515 shares were bought by its insiders, resulting in a net sale of 139,191 shares.
Arcutis Biotherapeutics Inc (ARQT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arcutis Biotherapeutics Inc Insider Transactions
Frazier Life Sciences Viii, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Frazier Life Sciences Viii, L.p.. You might contact Frazier Life Sciences Viii, L.p. via mailing address: 601 Union Street, Suite 3200, Seattle Wa 98101.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
